Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities
Author:
Publisher
Wiley
Subject
Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1016/j.molonc.2014.10.003/fullpdf
Reference63 articles.
1. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol,2008
2. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy;Barker;Clin. Pharmacol. Ther,2009
3. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy;Bremnes;Eur. J. Cancer,1995
4. CFR 312.84 - Risk-benefit Analysis in Review of Marketing Applications for Drugs to Treat Life-threatening and Severely-debilitating Illnesses
5. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma;Chinot;New Engl. J. Med,2014
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval;Journal of Clinical Epidemiology;2024-10
2. Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval;Journal of Pharmaceutical Innovation;2024-09-04
3. Strength of Statistical Evidence for the Efficacy of Cancer Drugs: A Bayesian Re-Analysis of Trials Supporting FDA Approval;2023-06-30
4. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials;Journal of Biopharmaceutical Statistics;2022-11-07
5. Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions;Pharmaceutical Medicine;2022-07-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3